Zobrazeno 1 - 10
of 163
pro vyhledávání: '"YUKO AOKI"'
Autor:
Takuma Minoura, Jun Yaokawa, Hiroaki Iwahori, Yuko Aoki, Mina Iwai, Shuxin Dong, Yasushi Iwata
Publikováno v:
MATERIALS TRANSACTIONS. 63:1258-1265
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6421757dd78c14db851888c98d2615d4
https://doi.org/10.2320/matertrans.f-m2022807
https://doi.org/10.2320/matertrans.f-m2022807
Autor:
Yoshinori Funama, Seitaro Oda, Fuyuhiko Teramoto, Yuko Aoki, Isao Takahashi, Shinichi Kojima, Taiga Goto, Kana Tanaka, Masafumi Kidoh, Yasunori Nagayama, Takeshi Nakaura, Toshinori Hirai
Publikováno v:
Journal of Medical Physics; Jan-Mar2024, Vol. 49 Issue 1, p127-132, 6p
Publikováno v:
JA Clinical Reports, Vol 3, Iss 1, Pp 1-4 (2017)
Abstract Background There has been an increase in the number of Japanese patients with lumbar spinal canal stenosis (LSCS) who complain of chronic pain or motor disturbance in the lower back or extremities. These patients are often treated with anti-
Externí odkaz:
https://doaj.org/article/4102f22835b74eb083c9dc93eaa83ece
Autor:
Nobuya Ishii, Masahiro Aoki, Yuko Aoki, Nukinori Akiyama, Kiyoaki Sakata, Toshihiko Fujii, Hitoshi Sase, Hideaki Mizuno, Yoshito Nakanishi
Supplementary Table S1 Genetic status information of cancer cell lines Supplementary Table S2 List of probe that is significantly modulated by CH5183284/Debio 1347 Supplementary Table S3 In vivo efficacy data of CH5183284/Debio 1347 Supplementary Fig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab405bf1d61ba72971efd6763b19725
https://doi.org/10.1158/1535-7163.22503531.v1
https://doi.org/10.1158/1535-7163.22503531.v1
Autor:
Nobuya Ishii, Yuko Aoki, Naoki Taka, Hirosato Ebiike, Toshiyuki Mio, Hidetoshi Shindoh, Kenji Morikami, Takehito Isobe, Hitoshi Sase, Kiyoaki Sakata, Toshihiko Fujii, Toshiyuki Tsukaguchi, Nukinori Akiyama, Yoshito Nakanishi
Supplementary Materials and Methods from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01026f8d65f8ae2359cbbdaf1c7f8e2
https://doi.org/10.1158/1535-7163.22501813
https://doi.org/10.1158/1535-7163.22501813
Autor:
Nobuya Ishii, Yuko Aoki, Naoki Taka, Hirosato Ebiike, Toshiyuki Mio, Hidetoshi Shindoh, Kenji Morikami, Takehito Isobe, Hitoshi Sase, Kiyoaki Sakata, Toshihiko Fujii, Toshiyuki Tsukaguchi, Nukinori Akiyama, Yoshito Nakanishi
Supplementary Figures S1-S7 and Table. S1: Determination of the binding mode of the FGFR inhibitor CH5183284/Debio 1347. S2: Effects of CH5183284/Debio 1347 and cediranib on in vitro VEGF-induced tube formation. S3: Kinase activity of FGFR2 WT, V564F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7730b1607e611f614d761c364343ce4c
https://doi.org/10.1158/1535-7163.22501816.v1
https://doi.org/10.1158/1535-7163.22501816.v1
Autor:
Yuko Aoki, Osamu Kondoh, Nobuya Ishii, Toshikazu Yamazaki, Yasushi Yoshimura, Keiichi Morita, Shino Kuramoto, Hirosato Ebiike, Jun Ohwada, Yukako Tachibana, Kiyoaki Sakata, Toshihiko Fujii, Hiromi Tanimura, Miyuki Yoshida, Hiroshi Tanaka
Purpose: The phosphatidylinositol 3-kinase (PI3K) pathway plays a central role in cell proliferation and survival in human cancer. PIK3CA mutations, which are found in many cancer patients, activate the PI3K pathway, resulting in cancer development a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662c38c75e05cc99955bf88044ca940c
https://doi.org/10.1158/1078-0432.c.6518331.v1
https://doi.org/10.1158/1078-0432.c.6518331.v1
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Tumors with mutant RAS are often dependent on extracellular signal–regulated kinase (ERK) signaling for growth; however, MEK inhibitors have only marginal antitumor activity in these tumors. MEK inhibitors relieve ERK-dependent feedback inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6d6624da24b766920d5ee7c74276a2
https://doi.org/10.1158/0008-5472.c.6504354.v1
https://doi.org/10.1158/0008-5472.c.6504354.v1
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Supplementary Figure S1 - PDF file 70K, Induction of p27Kip1 protein and cell cycle arrest by CH5126766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b272c3326137d6cf173146780cfce50
https://doi.org/10.1158/0008-5472.22395636.v1
https://doi.org/10.1158/0008-5472.22395636.v1
Autor:
Toshiyuki Sakai, Yuko Aoki, Neal Rosen, Poulikos I. Poulikakos, Yoshihiro Sowa, Mikio Arisawa, Nobuo Shimma, Toshihiro Aoki, Hitoshi Iikura, Yukako Tachibana-Kondo, Yasushi Tomii, Yutaka Matsuda, Hiroshi Sakamoto, Takaaki Miura, Kazuhiro Ohara, Eric W. Joseph, Naoki Harada, Nobuya Ishii
Supplementary Materials and Methods - PDF file 65K, Antibodies and kinase panel assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d3675432925f1de4e4eff25dee105c
https://doi.org/10.1158/0008-5472.22395624
https://doi.org/10.1158/0008-5472.22395624